nach oben

Tumor Biology

Erschienen in:

01.12.2015 | Research Article

Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma

verfasst von: Shudan Mao, Wenqi Yang, Limei Ai, Zhe Li, Jieping Jin

Erschienen in: Tumor Biology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to investigate the expression and significance of the transforming growth factor β type II receptor (TGFβRII) in diffuse large B cell lymphoma. All patients were enrolled at the First Affiliated Hospital of Liaoning Medical University between 2001 and 2007. The median follow-up period was 53.3 months. Of the 338 patients studied, 131 (38.76 %) had TGFβRII positive expression on immunohistochemistry. The 5 year survival rate was significantly higher in patients with TGFβRII expression than in those without TGFβRII expression (40.3 vs. 31.6 %, P = 0.041). Multivariate analysis identified TGFβRII expression as an independent predictive parameter for survival, in addition to lactate dehydrogenase, clinical stage, and histologic subtype. TGFβRII expression may be considered a new prognostic factor of diffuse large B cell lymphoma.

Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues (edition 4). Lyon: International Agency for Research on Cancer Press; 2008.

Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16:2780–95.CrossRefPubMed

Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.PubMed

Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol. 1999;111:S8–S12.PubMed

Coiffier B, Gisselbrecht C, Vose JM, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d’Etudes des Lymphomes Agressifs. J Clin Oncol. 1991;9:211–9.CrossRefPubMed

Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 1996;87:265–72.PubMed

Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a populationbased study. J Clin Oncol. 1996;14:2131–8.CrossRefPubMed

Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin’s lymphoma: a British National Lymphoma Investigation Study. Blood. 1996;88:1046–51.PubMed

Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood. 1997;90:244–51.PubMed

10.

Koduru PR, Raju K, Vadmal V, et al. Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin’s lymphoma. Blood. 1997;90:4078–91.PubMed

11.

Ichikawa A, Kinoshita T, Watanabe T, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med. 1997;337:529–34.CrossRefPubMed

12.

Zhang H, Gao J, Zhao Z, Li M, Liu C. Clinical implications of SPRR1A expression in diffuse large B-cell lymphomas: a prospective, observational study. BMC Cancer. 2014;14:333.CrossRefPubMedPubMedCentral

13.

Liu C, Lu Y, Wang B-b, Zhang Y-j, Zhang R-s, Lu Y, et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg. 2011;253:1165–71.CrossRefPubMed

14.

Liu C, Cao X, Zhang Y, Xu H, Zhang R, Wu Y, et al. Co-expression of Oct-4 and Nestin in human breast cancers. Mol Biol Rep. 2012;39:5875–81.CrossRefPubMed

15.

Xu D, Xu H, Ren Y, Liu C, Wang X, Zhang H, et al. Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS One. 2012;7(10):e46670.CrossRefPubMedPubMedCentral

16.

Hao Zhang, Yuan Ren, Huanming Xu, Deyan Pang, Chao Duan, Caigang Liu. The expression of stem cell protein Piwil2 and piR-932 in breast cancer. 2013 Aug 27. pii: S0960-7404(13)00066-2.

17.

Liu B, Nicolaides NC, Markowitz S, Willson JKV, Parsons RE, Jen J, et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet. 1995;9:48.CrossRefPubMed

18.

Thibodeau SN, French AJ, Roche PC, Cunningham JM, Tester DJ, Lindor NM, et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res. 1996;56:4836.PubMed

19.

Umar A, Boyer JC, Thomas DC, Nguyen DC, Risinger JI, Boyd J, et al. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J Biol Chem. 1994;269:14367.PubMed

20.

Boyer JC, Umar A, Risinger JI, Lipford JR, Kane M, Yin S, et al. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res. 1995;55:6063.PubMed

21.

Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair defective human tumor cell lines. Cancer Res. 1997;57:808.PubMed

22.

Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95:6870.CrossRefPubMedPubMedCentral

23.

Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, et al. hMLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet. 1999;8:661.CrossRefPubMed

24.

Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGFβ receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336.CrossRefPubMed

25.

Yamamoto H, Sawai H, Perucho M. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 1997;57:4420.PubMed

26.

Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 1997;275:967.CrossRefPubMed

27.

Schwartz Jr S, Yamamoto H, Navarro M, Maestro M, Reventos J, Perucho M. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 1999;59:2995.PubMed

28.

Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1:292–3.CrossRefPubMed

29.

Isufi I, Seetharam M, Zhou L, Sohal D, Opalinska J, et al. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. J Interferon Cytokine Res. 2007;27:543–52.CrossRefPubMed

30.

Santibanez JF, Quintanilla M, Bernabeu C. TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2011;121:233–51.CrossRef

31.

Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell. 1992;71:1003–14.CrossRefPubMed

32.

Derynck R, Zhang Y. Smad-dependent and Smad-independent pathways in TGF-family signalling. Nature. 2003;425:577–84.CrossRefPubMed

33.

Reiss M. TGF-beta and cancer. Microbes Infect. 1999;1:1327–47.CrossRefPubMed

34.

Rehmann JA, LeBien TW. Transforming growth factorbeta regulates normal human pre-Bcell differentiation. Int Immunol. 1994;6:315–22.CrossRefPubMed

35.

Kehrl JH, Thevenin C, Rieckmann P, et al. Transforming growth factor-beta suppresses human Blymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. J Immunol. 1991;146:4016–23.PubMed

36.

Smeland EB, Blomhoff HK, Holte H, et al. Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human Blymphocytes. Exp Cell Res. 1987;171:213–22.CrossRefPubMed

37.

Bouchard C, Fridman WH, Sautes C. Effect of TGF-beta1 on cell cycle regulatory proteins in LPS-stimulated normal mouse Blymphocytes. J Immunol. 1997;159:4155–64.PubMed

38.

Djaborkhel R, Tvrdik D, Eckschlager T, et al. Cyclin A down-regulation in TGFbeta1-arrested follicular lymphoma cells. Exp Cell Res. 2000;261:250–9.CrossRefPubMed

39.

Kehrl JH, Roberts AB, Wakefield LM, et al. Transforming growth factor beta is an important immunomodulatory protein for human Blymphocytes. J Immunol. 1986;137:3855–60.PubMed

40.

Wahl SM, Hunt DA, Wong HL, et al. Transforming growth factor is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol. 1988;140:3026–32.PubMed

41.

Ranges GE, Figari IS, Espevik T, et al. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med. 1987;166:991–8.CrossRefPubMed

42.

Lotz M, Ranheim E, Kipps TJ. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia Bcells. J Exp Med. 1994;179:999–1004.CrossRefPubMed

43.

Lebman DA, Edmiston JS. The role of TGF-beta in growth, differentiation, and maturation of Blymphocytes. Microbes Infect. 1999;1:1297–304.CrossRefPubMed

44.

Chaouchi N, Arvanitakis L, Auffredou MT, et al. Characterization of transforming growth factor-beta 1 induced apoptosis in normal human Bcells and lymphoma Bcell lines. Oncogene. 1995;11:1615–22.PubMed

Titel: Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma
verfasst von: Shudan Mao
Wenqi Yang
Limei Ai
Zhe Li
Jieping Jin
Publikationsdatum: 01.12.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 12/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3700-z

Springer Medizin

Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2015

High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC)

Shikonin inhibits invasiveness of osteosarcoma through MMP13 suppression

Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling

High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer

Cancer cell-derived IL-8 induces monocytic THP1 cells to secrete IL-8 via the mitogen-activated protein kinase pathway

Downregulation of the long noncoding RNA EGOT correlates with malignant status and poor prognosis in breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie